FDA Approves Cymbalta(R) For Treatment Of Generalized Anxiety Disorder: "
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalized anxiety disorder (GAD), a condition that affects more than 6.5 million American adults in a given year.(1) Because GAD presents with a variety of symptoms, it can be difficult to diagnose(2) and may have a negative impact on a person's ability to function properly in work, family and social situations.(3)"


Post a Comment

Google Analytics Alternative